Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Cheung

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Trials|June 18, 2020
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 17, 2015
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's EsophagusAndrew K Joe, Felice Schnoll-Sussman, Robert S Bresalier, et al.
Trials|November 18, 2020
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Trials|June 10, 2020
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Eclinicalmedicine|February 6, 2024
Rycal S48168 (ARM210) for <i>RYR1</i>-related myopathies: a phase one, open-label, dose-escalation trialJoshua J Todd, Tokunbor A Lawal, Irene C Chrismer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 6, 2025
Toward therapeutic trials in primary lateral sclerosisErica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Muscle & Nerve|March 2, 2026
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament AnalysesEric Sorenson, Daragh Heitzman, Ikjae Lee, et al.
Annals of Neurology|September 29, 2025
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes AssessmentIkjae Lee, Grace Jang, Ying Kuen Ken Cheung, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 28, 2022
Primary lateral sclerosis natural history study - planning, designing, and early enrollmentHiroshi Mitsumoto, Grace Jang, Ikjae Lee, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Trials|June 18, 2020
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 17, 2015
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's EsophagusAndrew K Joe, Felice Schnoll-Sussman, Robert S Bresalier, et al.
Trials|November 18, 2020
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Trials|June 10, 2020
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trialChristina M Eckhardt, Matthew J Cummings, Kartik N Rajagopalan, et al.
Eclinicalmedicine|February 6, 2024
Rycal S48168 (ARM210) for <i>RYR1</i>-related myopathies: a phase one, open-label, dose-escalation trialJoshua J Todd, Tokunbor A Lawal, Irene C Chrismer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 6, 2025
Toward therapeutic trials in primary lateral sclerosisErica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Muscle & Nerve|March 2, 2026
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament AnalysesEric Sorenson, Daragh Heitzman, Ikjae Lee, et al.
Annals of Neurology|September 29, 2025
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes AssessmentIkjae Lee, Grace Jang, Ying Kuen Ken Cheung, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 28, 2022
Primary lateral sclerosis natural history study - planning, designing, and early enrollmentHiroshi Mitsumoto, Grace Jang, Ikjae Lee, et al.
Pageof 9